Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil Impact on Pulmonary Circulation During Exercise in Healthy Humans
NCT04985929Phase 2Completed
- Sponsor
- University of Alberta
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sildenafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by University of Alberta. Primary endpoints: Diffusion capacity of carbon monoxide, Capillary blood volume and 1 more. Started Jul 2021; status: completed.
02
Drugs
sildenafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04985929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985929.